Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors

The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models

(2011) E Normant et al.   ONCOGENE

Treatment of HER2-overexpressing breast cancer

(2010) J. Baselga   ANNALS OF ONCOLOGY

17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells

(2010) Panagiotis K Karkoulis et al.   BMC CANCER

How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?

(2010) Yohannes Mebratu et al.   CELL CYCLE

Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy

(2010) James R Porter et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer

(2010) Dario C Altieri   Future Oncology

Expression of HSP90 in gastrointestinal stromal tumours and mesenchymal tumours

(2010) Gu Hyun Kang et al.   HISTOPATHOLOGY

Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions

(2010) Yasutomo Suzuki et al.   INTERNATIONAL JOURNAL OF UROLOGY

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma

(2010) Simon Pacey et al.   INVESTIGATIONAL NEW DRUGS

PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001

(2010) Morassa Mohseni et al.   JOURNAL OF CLINICAL INVESTIGATION

Heat Shock Protein 90 Inhibition in Lung Cancer

(2010) Takeshi Shimamura et al.   Journal of Thoracic Oncology

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

(2010) J E Lancet et al.   LEUKEMIA

HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way

(2010) Bin Peng et al.   Molecular Cancer

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin

(2009) X Wu et al.   BRITISH JOURNAL OF CANCER

TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells

(2009) Eleonora Costantino et al.   CANCER LETTERS

17 AAG for HSP90 Inhibition in Cancer – From Bench to Bedside

(2009) Saad Usmani et al.   CURRENT MOLECULAR MEDICINE

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

(2009) Shivaani Kummar et al.   EUROPEAN JOURNAL OF CANCER

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

(2009) Martin Kaiser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent

(2009) Britt Erika Hanson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Novel targets in esophageal and gastric cancer: beyond antiangiogenesis

(2009) Wooin Lee et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Heat shock protein inhibitors and vaccines as new agents in cancer treatment

(2009) Eleni M Karapanagiotou et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma

(2009) Marco Breinig et al.   HEPATOLOGY

Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial

(2009) Remi A. Nout et al.   JOURNAL OF CLINICAL ONCOLOGY

Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway

(2009) Edoardo Missiaglia et al.   JOURNAL OF CLINICAL ONCOLOGY

Heat Shock Protein 90: Inhibitors in Clinical Trials

(2009) Marco A. Biamonte et al.   JOURNAL OF MEDICINAL CHEMISTRY

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors

(2009) Barbro Eriksson et al.   NEUROENDOCRINOLOGY

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

(2009) E. Caldas-Lopes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression Pattern and Functional Relevance of Epidermal Growth Factor Receptor and Cyclooxygenase-2: Novel Chemotherapeutic Targets in Pancreatic Endocrine Tumors?

(2008) Frank Bergmann et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The Hsp90 molecular chaperone: an open and shut case for treatment

(2008) Laurence H. Pearl et al.   BIOCHEMICAL JOURNAL

The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas

(2008) Jeremy S. Abramson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

(2008) D. B. Solit et al.   CLINICAL CANCER RESEARCH

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer

(2008) Dongweon Song et al.   MOLECULAR CANCER THERAPEUTICS